Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era

Reem Karmali, Jeffrey M. Switchenko, Subir Goyal, Krithika Shanmugasundaram, Michael C. Churnetski, Bhaskar Kolla, Veronika Bachanova, James N. Gerson, Stefan K. Barta, Max J. Gordon, Alexey V. Danilov, Natalie S. Grover, Narendranath Epperla, Stephanie Mathews, Madelyn Burkart, Yazeed Sawalha, Brian T. Hill, Nilanjan Ghosh, Steven I. Park, David A. BondKami J. Maddocks, Talha Badar, Timothy S. Fenske, Mehdi Hamadani, Jin Guo, Mary Malecek, Brad S. Kahl, Peter Martin, Kristie A. Blum, Christopher R. Flowers, Jonathon B. Cohen

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Clinical outcomes and predictors of survival in patients with newly diagnosed mantle cell lymphoma (MCL) treated in the rituximab era (2000–2015) at 12 US academic centers were assessed to identify determinants of survival across age groups. Objectives were to characterize and compare practice patterns, outcomes and prognostic factors for survival in younger patients (age < 65) and older patients (age ≥ 65 years). Among 1162 patients included, 697 were younger and 465 were older. In younger patients, 2-year progression free survival (PFS) and overall survival (OS) rates were 79% and 92% respectively; blastoid histology, ECOG ≥ 2, and lack of maintenance rituximab (MR) remained statistically relevant to poor OS on univariate analysis (UVA) and multivariate analysis (MVA). In older patients, 2-year PFS and OS rates were 67% and 86% respectively; lack of maintenance rituximab remained significantly associated with inferior PFS and OS on UVA and MVA (p < 0.001). Two-year PFS rates were 79%, and 67% and 2-year OS rates were 92% and 86% for ages < 65 and ≥ 65 respectively (p < 0.001). First-line high-dose cytarabine exposure and/or MR lessened the negative impact of age on survival. Taken collectively, survival outcomes for older patients remain inferior to those of younger patients in the rituximab era. However, maintenance rituximab and potentially high-dose cytarabine-based induction can mitigate the negative impact of age on survival.

Original languageEnglish (US)
Pages (from-to)1374-1384
Number of pages11
JournalAmerican Journal of Hematology
Issue number11
Early online dateJul 29 2021
StatePublished - Nov 1 2021

Bibliographical note

Funding Information:
C.F. has received research from 4D, Abbvie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceutical, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm, Burroughs Wellcome Fund, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation, Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research. CF has consulted for Abbvie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche, Gilead, Karyopharm, Pharmacyclics/ Janssen, Spectrum.

Funding Information:
K.M. has received research funding from Pharmacyclics, BMS, Merck, Novartis. K.M. has consulted for Pharmacyclics, Janssen, Morphosys, Celgene, Beigene, Kite, Karyopharm, ADC Therapeutics, Seattle Genetics.

Publisher Copyright:
© 2021 Wiley Periodicals LLC.

PubMed: MeSH publication types

  • Journal Article
  • Multicenter Study
  • Research Support, N.I.H., Extramural


Dive into the research topics of 'Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era'. Together they form a unique fingerprint.

Cite this